TP53 disruption is well recognized as an adverse prognostic factor in the setting of conventional chemotherapy and fixed duration venetoclax-based therapy but its prognostic significance for patients receiving continuous targeted treatment in the frontline is not fully established. In order to address this issue, ERIC is conducting a retrospective multicenter study of real-world clinical outcomes of TP53 mutated and/or deleted CLL treated with chemotherapy-free frontline targeted therapies, particularly focusing on continuous treatment.
The study is coordinated by Sunil Iyengar (London, UK).
|
